| Pembrolizumab for the treatment of non–small-cell lung cancer EB Garon, NA Rizvi, R Hui, N Leighl, AS Balmanoukian, JP Eder, ... New England Journal of Medicine 372 (21), 2018-2028, 2015 | 6503 | 2015 |
| Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients RS Herbst, JC Soria, M Kowanetz, GD Fine, O Hamid, MS Gordon, ... Nature 515 (7528), 563-567, 2014 | 5413 | 2014 |
| Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer JC Soria, Y Ohe, J Vansteenkiste, T Reungwetwattana, B Chewaskulyong, ... New England journal of medicine 378 (2), 113-125, 2018 | 4525 | 2018 |
| Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors B Routy, E Le Chatelier, L Derosa, CPM Duong, MT Alou, R Daillère, ... Science 359 (6371), 91-97, 2018 | 4514 | 2018 |
| DNA repair by ERCC1 in non–small-cell lung cancer and cisplatin-based adjuvant chemotherapy KA Olaussen, A Dunant, P Fouret, E Brambilla, F André, V Haddad, ... New England Journal of Medicine 355 (10), 983-991, 2006 | 2343 | 2006 |
| Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC SS Ramalingam, J Vansteenkiste, D Planchard, BC Cho, JE Gray, Y Ohe, ... New England Journal of Medicine 382 (1), 41-50, 2020 | 2163 | 2020 |
| Immune-related adverse events with immune checkpoint blockade: a comprehensive review JM Michot, C Bigenwald, S Champiat, M Collins, F Carbonnel, ... European journal of cancer 54, 139-148, 2016 | 2109 | 2016 |
| Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer M Peifer, L Fernández-Cuesta, ML Sos, J George, D Seidel, LH Kasper, ... Nature genetics 44 (10), 1104-1110, 2012 | 1481 | 2012 |
| AACR Project GENIE: powering precision medicine through an international consortium AACR Project Genie Consortium, AACR Project GENIE Consortium, ... Cancer discovery 7 (8), 818-831, 2017 | 1309 | 2017 |
| Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1 S Champiat, L Dercle, S Ammari, C Massard, A Hollebecque, ... Clinical Cancer Research 23 (8), 1920-1928, 2017 | 1228 | 2017 |
| First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study JC Soria, DSW Tan, R Chiari, YL Wu, L Paz-Ares, J Wolf, SL Geater, ... The Lancet 389 (10072), 917-929, 2017 | 1223 | 2017 |
| Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination C Boutros, A Tarhini, E Routier, O Lambotte, FL Ladurie, F Carbonnel, ... Nature reviews Clinical oncology 13 (8), 473-486, 2016 | 1056 | 2016 |
| Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper S Champiat, O Lambotte, E Barreau, R Belkhir, A Berdelou, F Carbonnel, ... Annals of Oncology 27 (4), 559-574, 2016 | 1018 | 2016 |
| Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) F Barlesi, J Mazieres, JP Merlio, D Debieuvre, J Mosser, H Lena, ... The Lancet 387 (10026), 1415-1426, 2016 | 954 | 2016 |
| A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study R Sun, EJ Limkin, M Vakalopoulou, L Dercle, S Champiat, SR Han, ... The Lancet Oncology 19 (9), 1180-1191, 2018 | 948 | 2018 |
| Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy JM Pitt, A Marabelle, A Eggermont, JC Soria, G Kroemer, L Zitvogel Annals of Oncology 27 (8), 1482-1492, 2016 | 922 | 2016 |
| Management of non-small-cell lung cancer: recent developments M Reck, DF Heigener, T Mok, JC Soria, KF Rabe The Lancet 382 (9893), 709-719, 2013 | 840 | 2013 |
| Rociletinib in EGFR-mutated non–small-cell lung cancer LV Sequist, JC Soria, JW Goldman, HA Wakelee, SM Gadgeel, A Varga, ... New England Journal of Medicine 372 (18), 1700-1709, 2015 | 825 | 2015 |
| Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer V Subbiah, RJ Kreitman, ZA Wainberg, JY Cho, JHM Schellens, JC Soria, ... Journal of Clinical Oncology 36 (1), 7-13, 2018 | 818 | 2018 |
| T-cell–inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 … PA Ott, YJ Bang, SA Piha-Paul, ARA Razak, J Bennouna, JC Soria, ... Journal of Clinical Oncology 37 (4), 318-327, 2019 | 769 | 2019 |
